top of page
CUBE log_edited.png
2019 NEWS

Company news

Anchor 1


Cube and BioGaia futher expand their collaboaration for the promotion of the patented and world's most studied oral health probiotic, BioGaia Prodentis.

BioGaia Prodentis contains the unique combination of two probiotic strains, L.reuteri Protectis (DSM 17938 and Lactobacillus reuteri ATCC PTA 5289. The two strains work synergistically in the mouth and help the good microorganisms keep a natural balance in the mouth.

In numerous clinical studies it has been proven that BioGaia Prodentis is effective as a prophylactic measure as well as adjunctive treatment in reducing,




•  Caries

•  Pregnancy gingivitis

Latest clinical study did show that the use of BioGaia Prodentis helped maintaining dental implants.


Product news


BioGaia’s probiotic decreases pain in patients with diverticulitis


A randomized, double-blind, placebo-controlled study with BioGaia’s probiotic strain Lactobacillus reuteri ATCC PTA 4659 was shown to reduce abdominal pain significantly more than placebo in patients with acute uncomplicated diverticulitis. 

The study included 88 patients, 34 males and 54 females, diagnosed with acute uncomplicated diverticulitis. Mean age was 62 years. All patients were given standard antibiotic therapy for one week. Half of the group were additionally supplemented by Lactobacillus reuteri 4659 for 10 days, while the other half were given a placebo.

The results showed that supplementation of Lactobacillus reuteri 4659 significantly reduced abdominal pain and inflammation compared to placebo. Moreover, mean hospital stay in the probiotic group was 3.8 days compared to 4.8 days in the placebo group, a significant difference in time which results in economic benefits.

“Our study shows that supplementation with Lactobacillus reuteri 4659 twice a day for 10 days during the acute phase of uncomplicated diverticulitis results in reduction of both pain and inflammation, as well as shorter hospital stay. Based on these findings we suggest that patients with acute uncomplicated diverticulitis should be supplemented with this strain as a complement to standard antibiotic treatment,” says Principal Investigator Veronica Ojetti, Associate Professor at the Catholic University of the Sacred Heart in Rome, Italy.

The anti-inflammatory strain Lactobacillus reuteri 4659
BioGaia’s probiotic strain Lactobacillus reuteri ATCC PTA 4659 has in experimental models been shown to have strong anti-inflammatory properties, indicating potential positive effects in inflammatory conditions of the intestines. The now published study is the first randomized, double-blind, placebo-controlled study using an anti-inflammatory probiotic as an adjuvant in standard antibiotic therapy for acute uncomplicated diverticulitis.

What is diverticulitis?
It is common, especially after the age of 40, to have small, bulging pouches in the lining of the digestive tract. The condition known as diverticulitis occurs when one or more of these pouches become inflamed or infected, something that can cause severe abdominal pain, but also fever, nausea and changes in bowel habits.

Anchor 2


Lactobacillus reuteri, the only probiotic mentioned in article on colic in the New York Times: “We know that those drops can help,” says Dr Marc Rhoads


The article “All Babies Cry, but How Much Is Too Much?” in the New York Times Parenting Section explains what colic is, what do to and when to worry. In the section “If you breastfeed, consider probiotics” Lactobacillus reuteriis the only probiotic mentioned and it includes links to our products in the USA. The article was published 2 July 2019.

BioGaia colics.jpg
Anchor 3


In a double-blind, randomized and placebo-controlled study Lactobacillus reuteri Gastrus, in combination with so called quadruple therapy, was shown to improve eradication rate of infections caused by the bacterium Helicobacter pylori. Further, supplementation of Lactobacillus reuteri Gastrus significantly reduced side-effects of the treatment.


This is the first clinical study in patients with H. pylori infection, treated with quadruple therapy and supplemented by Lactobacillus reuteri Gastrus. The study enrolled 100 patients, divided into four groups. All patients received quadruple therapy and in two of the groups Lactobacillus reuteri Gastrus was added.

Treatment success was defined as a cure rate of more than 95% and this was achieved in the group treated for 14 days and supplemented by Lactobacillus reuteri Gastrus.


The difference compared to the other groups was not statistically significant. However, all other groups had cure rates below 90%, which is regarded as treatment failure.

Supplementation of Lactobacillus reuteri Gastrus significantly reduced treatment-related side-effects; incidence of nausea and vomiting, abdominal pain, and bitter taste.

bottom of page